Published in

Springer (part of Springer Nature), Clinical Autonomic Research, 1(13), p. 51-53

DOI: 10.1007/s10286-003-0034-5

Links

Tools

Export citation

Search in Google Scholar

Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy

Journal article published in 2003 by Ryuji Sakakibara, Tomoyuki Uchiyama, Masato Asahina, Mitsuharu Yoshiyama ORCID, Tomonori Yamanishi, Takamichi Hattori
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In 5 patients with multiple system atrophy, administration of 15 mg/day of amezinium metilsulfate, an adrenergic agent, during 6 months for the treatment of postural hypotension exacerbated post-micturition residuals as compared to that before treatment (178 ml versus 113 ml for a change of 37 %, p < 0.05). Amezinium metilsulfate most probably stimulates both alpha1B-receptors in the vascular wall and alpha1A/D-receptors in the proximal urethra.